Establishment Labs Holdings Inc. (ESTA)
| Market Cap | 2.17B +98.3% |
| Revenue (ttm) | 245.82M +38.6% |
| Net Income | -38.89M |
| EPS | -1.29 |
| Shares Out | 29.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 588,680 |
| Open | 71.52 |
| Previous Close | 71.52 |
| Day's Range | 71.01 - 73.49 |
| 52-Week Range | 36.53 - 97.59 |
| Beta | 1.09 |
| Analysts | Strong Buy |
| Price Target | 102.44 (+40.97%) |
| Earnings Date | Aug 6, 2026 |
About ESTA
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales force. Establishment Labs Holdings Inc. was incorporated in 2004 and i... [Read more]
Financial Performance
In 2025, ESTA's revenue was $211.08 million, an increase of 27.14% compared to the previous year's $166.03 million. Losses were -$51.06 million, -39.64% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ESTA stock is "Strong Buy." The 12-month stock price target is $102.44, which is an increase of 40.97% from the latest price.
News
Establishment Labs upgraded to Buy from Neutral at Citi
Citi upgraded Establishment Labs (ESTA) to Buy from Neutral with a $92 price target
Citi upgrades Establishment Labs to Buy on recent pullback
Citi upgraded Establishment Labs (ESTA) to Buy from Neutral with an unchanged price target of $92. The shares didn’t rally post earnings despite Establishment posting a strong quarter, the analyst…
Establishment Labs price target raised to $105 from $90 at Canaccord
Canaccord analyst Caitlin Roberts raised the firm’s price target on Establishment Labs (ESTA) to $105 from $90 and keeps a Buy rating on the shares. The firm said they posted…
Establishment Labs price target raised to $103 from $96 at BTIG
BTIG raised the firm’s price target on Establishment Labs (ESTA) to $103 from $96 and keeps a Buy rating on the shares. Establishment Labs delivered another strong quarter with revenue…
Establishment Labs Holdings Earnings Call Transcript: Q2 2026
Q2 revenue grew 31.7% year-over-year to $67.5 million, with U.S. sales up 140.9% and strong adoption of Minimally Invasive procedures. Full-year guidance was raised to $269–$271 million, with continued margin expansion and positive cash flow.
Establishment Labs Holdings Earnings release: Q2 2026
Establishment Labs Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Establishment Labs Holdings Quarterly report: Q2 2026
Establishment Labs Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Establishment Labs® Reports Second Quarter 2026 Financial Results
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in bre...
Establishment Labs price target raised to $117 from $95 at TD Cowen
TD Cowen raised the firm’s price target on Establishment Labs (ESTA) to $117 from $95 and keeps a Buy rating on the shares. The firm said they see opportunities for…
Establishment Labs® to Announce Second Quarter 2026 Financial Results on August 6
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in bre...
Establishment Labs price target raised to $105 from $100 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Establishment Labs (ESTA) to $105 from $100 and keeps an Outperform rating on the shares. The firm adjusted targets in…
Establishment Labs price target raised to $96 from $90 at BTIG
BTIG analyst Sam Eiber raised the firm’s price target on Establishment Labs (ESTA) to $96 from $90 and keeps a Buy rating on the shares as part of a broader…
Establishment Labs price target raised to $92 from $76 at Citi
Citi raised the firm’s price target on Establishment Labs (ESTA) to $92 from $76 and keeps a Neutral rating on the shares. For Q2 earnings season, given “the skittish trading…
Establishment Labs appoints Taylor Harris to Board of Directors
Establishment Labs (ESTA) announced the appointment of Taylor Harris to its Board of Directors. Most recently, Harris served as Chief Executive Officer of Cutera.
Establishment Labs® Appoints Taylor Harris to Board of Directors
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in bre...
Establishment Labs added to membership of U.S. small-cap Russell 2000 Index
Establishment Labs (ESTA) will be added as a member of the US small-cap Russell 2000 Index, effective when the US market opens on June 29th as part of the 2026…
Establishment Labs® Added to Membership of U.S. Small-Cap Russell 2000® Index
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in bre...
Establishment Labs Holdings Transcript: AGM 2026
The meeting was held virtually with all directors and key executives present. Shareholders approved the election of six directors, executive compensation, and the appointment of auditors, with no questions raised. Final voting results will be filed with the SEC.
Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer
WEST JORDAN, Utah, May 18, 2026 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular interventi...
Establishment Labs price target raised to $90 from $88 at BTIG
BTIG raised the firm’s price target on Establishment Labs (ESTA) to $90 from $88 and keeps a Buy rating on the shares. The company’s results were driven by continued U.S.
Establishment Labs price target raised to $76 from $65 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on Establishment Labs (ESTA) to $76 from $65 and keeps a Neutral rating on the shares. The firm says this was…
Establishment Labs Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw 45% revenue growth, gross margin expansion to 70.7%, and strong U.S. momentum, driven by Motiva adoption and minimally invasive platform launches. Guidance was raised for 2026, with continued profitability and cash flow positive expected in H2.
Establishment Labs Holdings Earnings release: Q1 2026
Establishment Labs Holdings released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Establishment Labs Holdings Quarterly report: Q1 2026
Establishment Labs Holdings has published its Q1 2026 quarterly earnings report on May 6, 2026.
Establishment Labs Reports First Quarter 2026 Financial Results
NEW YORK--(BUSINESS WIRE)---- $ESTA #Breast--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in bre...